Atai Life Sciences N.V. (ATAI)
- Previous Close
1.8400 - Open
1.8500 - Bid 1.9100 x 800
- Ask 1.9400 x 600
- Day's Range
1.8250 - 1.9425 - 52 Week Range
1.0250 - 2.8500 - Volume
873,501 - Avg. Volume
1,616,222 - Market Cap (intraday)
323.107M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2500 - Earnings Date May 7, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.68
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
www.atai.lifeRecent News: ATAI
Performance Overview: ATAI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATAI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATAI
Valuation Measures
Market Cap
323.11M
Enterprise Value
162.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
976.27
Price/Book (mrq)
1.33
Enterprise Value/Revenue
519.08
Enterprise Value/EBITDA
-4.49
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.52%
Return on Equity (ttm)
-17.21%
Revenue (ttm)
314k
Net Income Avi to Common (ttm)
-40.22M
Diluted EPS (ttm)
-0.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
179.26M
Total Debt/Equity (mrq)
8.82%
Levered Free Cash Flow (ttm)
-37.17M